Selected research
Market Structure
Global Anti-HMGB1 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-HMGB1 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-HMGB1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-HMGB1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-HMGB1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-HMGB1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-HMGB1 Antibody include Abcam, Arigo Biolaboratories, Atlas Antibodies, BioLegend, BosterBio, Chondrex, Genetex, Leadgene Biomedical and Raybiotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-HMGB1 Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-HMGB1 Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-HMGB1 Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-HMGB1 Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-HMGB1 Antibody Segment by Company
Abcam
Arigo Biolaboratories
Atlas Antibodies
BioLegend
BosterBio
Chondrex
Genetex
Leadgene Biomedical
Raybiotech
St John's Laboratory
Thermo Fisher Scientific
Merck
Sino Biological
Anti-HMGB1 Antibody Segment by Type
Rabbit Anti-HMGB1 Antibody
Mouse Anti-HMGB1 Antibody
Anti-HMGB1 Antibody Segment by Application
ELISA
Immunofluorescence
Western Blot
Others
Anti-HMGB1 Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-HMGB1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-HMGB1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-HMGB1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-HMGB1 Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-HMGB1 Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-HMGB1 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-HMGB1 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Rabbit Anti-HMGB1 Antibody
- Mouse Anti-HMGB1 Antibody
Applications
- ELISA
- Immunofluorescence
- Western Blot
- Others
Companies covered
- Abcam
- Arigo Biolaboratories
- Atlas Antibodies
- BioLegend
- BosterBio
- Chondrex
- Genetex
- Leadgene Biomedical
- Raybiotech
- St John's Laboratory
- Thermo Fisher Scientific
- Merck
- Sino Biological
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-HMGB1 Antibody Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-HMGB1 Antibody Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-HMGB1 Antibody Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-HMGB1 Antibody Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-HMGB1 Antibody Market Dynamics
- 2.1 Anti-HMGB1 Antibody Industry Trends
- 2.2 Anti-HMGB1 Antibody Industry Drivers
- 2.3 Anti-HMGB1 Antibody Industry Opportunities and Challenges
- 2.4 Anti-HMGB1 Antibody Industry Restraints
3 Anti-HMGB1 Antibody Market by Manufacturers
- 3.1 Global Anti-HMGB1 Antibody Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-HMGB1 Antibody Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-HMGB1 Antibody Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-HMGB1 Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-HMGB1 Antibody Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-HMGB1 Antibody Manufacturers, Product Type & Application
- 3.7 Global Anti-HMGB1 Antibody Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-HMGB1 Antibody Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-HMGB1 Antibody Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-HMGB1 Antibody Tier 1, Tier 2, and Tier 3
4 Anti-HMGB1 Antibody Market by Type
- 4.1 Anti-HMGB1 Antibody Type Introduction
- 4.1.1 Rabbit Anti-HMGB1 Antibody
- 4.1.2 Mouse Anti-HMGB1 Antibody
- 4.2 Global Anti-HMGB1 Antibody Sales by Type
- 4.2.1 Global Anti-HMGB1 Antibody Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-HMGB1 Antibody Sales by Type (2021-2032)
- 4.2.3 Global Anti-HMGB1 Antibody Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-HMGB1 Antibody Revenue by Type
- 4.3.1 Global Anti-HMGB1 Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-HMGB1 Antibody Revenue by Type (2021-2032)
- 4.3.3 Global Anti-HMGB1 Antibody Revenue Market Share by Type (2021-2032)
5 Anti-HMGB1 Antibody Market by Application
- 5.1 Anti-HMGB1 Antibody Application Introduction
- 5.1.1 ELISA
- 5.1.2 Immunofluorescence
- 5.1.3 Western Blot
- 5.1.4 Others
- 5.2 Global Anti-HMGB1 Antibody Sales by Application
- 5.2.1 Global Anti-HMGB1 Antibody Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-HMGB1 Antibody Sales by Application (2021-2032)
- 5.2.3 Global Anti-HMGB1 Antibody Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-HMGB1 Antibody Revenue by Application
- 5.3.1 Global Anti-HMGB1 Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-HMGB1 Antibody Revenue by Application (2021-2032)
- 5.3.3 Global Anti-HMGB1 Antibody Revenue Market Share by Application (2021-2032)
6 Global Anti-HMGB1 Antibody Sales by Region
- 6.1 Global Anti-HMGB1 Antibody Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-HMGB1 Antibody Sales by Region (2021-2032)
- 6.2.1 Global Anti-HMGB1 Antibody Sales by Region (2021-2026)
- 6.2.2 Global Anti-HMGB1 Antibody Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-HMGB1 Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-HMGB1 Antibody Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-HMGB1 Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-HMGB1 Antibody Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-HMGB1 Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-HMGB1 Antibody Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-HMGB1 Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-HMGB1 Antibody Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-HMGB1 Antibody Revenue by Region
- 7.1 Global Anti-HMGB1 Antibody Revenue by Region
- 7.1.1 Global Anti-HMGB1 Antibody Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-HMGB1 Antibody Revenue by Region (2021-2026)
- 7.1.3 Global Anti-HMGB1 Antibody Revenue by Region (2027-2032)
- 7.1.4 Global Anti-HMGB1 Antibody Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-HMGB1 Antibody Revenue (2021-2032)
- 7.2.2 North America Anti-HMGB1 Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-HMGB1 Antibody Revenue (2021-2032)
- 7.3.2 Europe Anti-HMGB1 Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-HMGB1 Antibody Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-HMGB1 Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-HMGB1 Antibody Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-HMGB1 Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Abcam
- 8.1.1 Abcam Company Information
- 8.1.2 Abcam Business Overview
- 8.1.3 Abcam Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Abcam Anti-HMGB1 Antibody Product Portfolio
- 8.1.5 Abcam Recent Developments
- 8.2 Arigo Biolaboratories
- 8.2.1 Arigo Biolaboratories Company Information
- 8.2.2 Arigo Biolaboratories Business Overview
- 8.2.3 Arigo Biolaboratories Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Arigo Biolaboratories Anti-HMGB1 Antibody Product Portfolio
- 8.2.5 Arigo Biolaboratories Recent Developments
- 8.3 Atlas Antibodies
- 8.3.1 Atlas Antibodies Company Information
- 8.3.2 Atlas Antibodies Business Overview
- 8.3.3 Atlas Antibodies Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Atlas Antibodies Anti-HMGB1 Antibody Product Portfolio
- 8.3.5 Atlas Antibodies Recent Developments
- 8.4 BioLegend
- 8.4.1 BioLegend Company Information
- 8.4.2 BioLegend Business Overview
- 8.4.3 BioLegend Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 BioLegend Anti-HMGB1 Antibody Product Portfolio
- 8.4.5 BioLegend Recent Developments
- 8.5 BosterBio
- 8.5.1 BosterBio Company Information
- 8.5.2 BosterBio Business Overview
- 8.5.3 BosterBio Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 BosterBio Anti-HMGB1 Antibody Product Portfolio
- 8.5.5 BosterBio Recent Developments
- 8.6 Chondrex
- 8.6.1 Chondrex Company Information
- 8.6.2 Chondrex Business Overview
- 8.6.3 Chondrex Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Chondrex Anti-HMGB1 Antibody Product Portfolio
- 8.6.5 Chondrex Recent Developments
- 8.7 Genetex
- 8.7.1 Genetex Company Information
- 8.7.2 Genetex Business Overview
- 8.7.3 Genetex Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Genetex Anti-HMGB1 Antibody Product Portfolio
- 8.7.5 Genetex Recent Developments
- 8.8 Leadgene Biomedical
- 8.8.1 Leadgene Biomedical Company Information
- 8.8.2 Leadgene Biomedical Business Overview
- 8.8.3 Leadgene Biomedical Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Leadgene Biomedical Anti-HMGB1 Antibody Product Portfolio
- 8.8.5 Leadgene Biomedical Recent Developments
- 8.9 Raybiotech
- 8.9.1 Raybiotech Company Information
- 8.9.2 Raybiotech Business Overview
- 8.9.3 Raybiotech Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Raybiotech Anti-HMGB1 Antibody Product Portfolio
- 8.9.5 Raybiotech Recent Developments
- 8.10 St John's Laboratory
- 8.10.1 St John's Laboratory Company Information
- 8.10.2 St John's Laboratory Business Overview
- 8.10.3 St John's Laboratory Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 St John's Laboratory Anti-HMGB1 Antibody Product Portfolio
- 8.10.5 St John's Laboratory Recent Developments
- 8.11 Thermo Fisher Scientific
- 8.11.1 Thermo Fisher Scientific Company Information
- 8.11.2 Thermo Fisher Scientific Business Overview
- 8.11.3 Thermo Fisher Scientific Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Thermo Fisher Scientific Anti-HMGB1 Antibody Product Portfolio
- 8.11.5 Thermo Fisher Scientific Recent Developments
- 8.12 Merck
- 8.12.1 Merck Company Information
- 8.12.2 Merck Business Overview
- 8.12.3 Merck Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Merck Anti-HMGB1 Antibody Product Portfolio
- 8.12.5 Merck Recent Developments
- 8.13 Sino Biological
- 8.13.1 Sino Biological Company Information
- 8.13.2 Sino Biological Business Overview
- 8.13.3 Sino Biological Anti-HMGB1 Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Sino Biological Anti-HMGB1 Antibody Product Portfolio
- 8.13.5 Sino Biological Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-HMGB1 Antibody Value Chain Analysis
- 9.1.1 Anti-HMGB1 Antibody Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-HMGB1 Antibody Production Mode & Process
- 9.2 Anti-HMGB1 Antibody Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-HMGB1 Antibody Distributors
- 9.2.3 Anti-HMGB1 Antibody Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst